Vogenx Inc Common Stock (VOGX) - Total Assets
Based on the latest financial reports, Vogenx Inc Common Stock (VOGX) holds total assets worth $898.46K USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vogenx Inc Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how Vogenx Inc Common Stock's total assets have evolved over time, based on quarterly financial data. Also see how much is Vogenx Inc Common Stock worth for the company's overall valuation and market capitalisation.
Vogenx Inc Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Vogenx Inc Common Stock's total assets of $898.46K consist of 100.0% current assets and 0.0% non-current assets. Review Vogenx Inc Common Stock (VOGX) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Vogenx Inc Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See VOGX stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vogenx Inc Common Stock's current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2024.
- Cash Position: Cash and equivalents constituted 88.2% of total assets in 2025, down from 99.2% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Vogenx Inc Common Stock Competitors by Total Assets
Key competitors of Vogenx Inc Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Vogenx Inc Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.39 | - | - |
| Quick Ratio | 0.39 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $-1.40 Million | - | - |
Vogenx Inc Common Stock - Advanced Valuation Insights
This section examines the relationship between Vogenx Inc Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 649.88 |
| Asset Growth Rate (YoY) | -29.8% |
| Total Assets | $681.17K |
| Market Capitalization | $442.68 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Vogenx Inc Common Stock's assets at a significant premium (649.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Vogenx Inc Common Stock's assets decreased by 29.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vogenx Inc Common Stock (2024–2025)
The table below shows the annual total assets of Vogenx Inc Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $681.17K | -29.81% |
| 2024-12-31 | $970.40K | -- |
About Vogenx Inc Common Stock
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party pay… Read more